Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) shares dropped 8.8% during trading on Tuesday . The company traded as low as $79.97 and last traded at $80.21. Approximately 82,870 shares were traded during trading, a decline of 47% from the average daily volume of 156,157 shares. The stock had previously closed at $87.91. Analysts […]
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Sees Large Drop in Short Interest theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
HC Wainwright restated their buy rating on shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) in a research report released on Wednesday morning, Benzinga reports. The firm currently has a $144.00 price objective on the biotechnology company’s stock. LGND has been the topic of a number of other research reports. Barclays cut their price target […]
Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) had its price objective trimmed by Barclays from $120.00 to $110.00 in a research report report published on Tuesday, Marketbeat reports. The brokerage currently has an overweight rating on the biotechnology company’s stock. Other equities research analysts also recently issued reports about the company. HC Wainwright increased their price […]
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) had its price objective dropped by equities researchers at Barclays from $120.00 to $110.00 in a report issued on Tuesday, MarketBeat.com reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price target would indicate a potential upside of 63.96% from the stock’s previous […]